Bayer's AskBio checks off another early win for gene therapy platform with Parkinson's safety data

Bayer’s AskBio gene therapy unit has achieved a key safety milestone in an early-stage trial for an investigational Parkinson’s disease treatment that must be delivered surgically into the brain.